Back
6
Total Score
Reviewed by
1 scientist
7
Evidence
5
Balance
7
Clarity
Share on Twitter

Reviews

LW
Luke Weymouth
Reviewed on 4 Nov 2024
7
Evidence
5
Balance
7
Clarity

This article is relatively clear and provides evidence and quotes from several sources bemoaning the fact that Donanemab will not be available on the NHS. I would however question the balance of the article, which contains no sources backing the move and provides little background as to why this drug won't be available besides it being "too expensive".

0
Thank you for reporting this comment, this will be passed on to administrators.